International Journal of Gynecology & Obstetrics

Clinical articles

Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome

Spiros Dendrinos

2nd Department of Obstetrics and Gynecology, “Aretaieion” Hospital, Medical School, University of Athens, Athens, Greece

Search for more papers by this author

Evangelos Sakkas,

Corresponding Author

Evangelos Sakkas

[email protected]

“MITERA” Private Maternity, Athens, Greece

Corresponding author. 169 Michalakopoulou Street, 11527, Athens, Greece. Tel.: +30 6944146944; fax: +30 2107758562.Search for more papers by this author

Evangelos Makrakis,

Evangelos Makrakis

2nd Department of Obstetrics and Gynecology, “Aretaieion” Hospital, Medical School, University of Athens, Athens, Greece

Search for more papers by this author

Spiros Dendrinos,

Spiros Dendrinos

2nd Department of Obstetrics and Gynecology, “Aretaieion” Hospital, Medical School, University of Athens, Athens, Greece

Search for more papers by this author

Evangelos Sakkas,

Corresponding Author

Evangelos Sakkas

[email protected]

“MITERA” Private Maternity, Athens, Greece

Corresponding author. 169 Michalakopoulou Street, 11527, Athens, Greece. Tel.: +30 6944146944; fax: +30 2107758562.Search for more papers by this author

Evangelos Makrakis,

Evangelos Makrakis

2nd Department of Obstetrics and Gynecology, “Aretaieion” Hospital, Medical School, University of Athens, Athens, Greece

Search for more papers by this author

First published: 29 December 2008

https://doi.org/10.1016/j.ijgo.2008.11.010

Citations: 69

Share a link

Email
Facebook
x
LinkedIn
Reddit
Wechat

Abstract

Objective

To compare low-molecular-weight (LMW) heparin plus low-dose aspirin with intravenous immunoglobulin (IVIG) in the treatment of antiphospholipid antibody syndrome in women with recurrent spontaneous abortions before 10 weeks of gestation.

Method

This prospective, multicenter trial conducted between 2002 and 2006 included 85 patients aged 18–39 years. The women were allocated randomly to receive LMW heparin plus low-dose aspirin, or IVIG. Data were compared using the t test and Fisher exact test.

Results

The women treated with LMW heparin plus low-dose aspirin had a higher rate of live births than those treated with IVIG (P = 0.003). Of those who completed the study, 29/40 (72.5%) and 15/38 (39.5%), respectively, had live births. Intent-to-treat analysis revealed a significant difference between the 2 groups (OR 1.802; 95%CI, 1.14–2.84; P = 0.007).

Conclusions

LMW heparin plus low-dose aspirin resulted in a higher live birth rate than IVIG in the treatment of antiphospholipid antibody syndrome in women with recurrent abortion.

References

[1]McNeil H.P., Chesterman C.N., Krilis S.A.. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol. 73, (4): 1989; 506–513
10.1111/j.1365-2141.1989.tb00289.x
PubMedWeb of Science®Google Scholar
[2]Kutteh W.H., Pasquarette M.. Recurrent pregnancy loss. J.A. Rock. Advances in obstetrics and gynecology. 2 ed. 1995; Mosby-Year book: St Louis; 147–177
Google Scholar
[3]Nilsson I., Astedt B., Hedner U., Berezin D.. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand. 197, (3): 1975; 153–159
10.1111/j.0954-6820.1975.tb04897.x
PubMedWeb of Science®Google Scholar
[4]Salafia C.M., Cowchock F.S.. Placental pathology and antiphospholipid antibodies: a descriptive study. Am J Perinatol. 14, (8): 1997; 435–441
10.1055/s-2007-994176
PubMedWeb of Science®Google Scholar
[5]Rand J.H., Wu X.X., Guller S., Gil J., Guha A., Scher J., et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol. 171, (6): 1994; 1566–1572
10.1016/0002-9378(94)90403-0
PubMedWeb of Science®Google Scholar
[6]Rand J.H., Wu X.X., Andree H., Lockwood C., Guller S., Scher J., et al. Pregnancy loss in the anti-phospholipid antibody syndrome – a possible thrombogenic mechanism. N Engl J Med. 337, (3): 1997; 154–160
10.1056/NEJM199707173370303
PubMedWeb of Science®Google Scholar
[7]Chamley L.W., Duncalf A.M., Mitchell M.D., Johnson P.M.. Action of anticardiolipin and antibodies to beta-2-glycoprotein-1 on trophoblast proliferation as a mechanism for fetal death. Lancet. 352, (9133): 1998; 1037–1038
10.1016/S0140-6736(05)60080-3
PubMedWeb of Science®Google Scholar
[8]Triplett D.A.. Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol. 20, (2): 1989; 52–67
10.1111/j.1600-0897.1989.tb00639.x
PubMedWeb of Science®Google Scholar
[9]Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42, (7): 1999; 1309–1311
10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
CASPubMedWeb of Science®Google Scholar
[10]Rai R., Cohen H., Dave M., Regan L.. Randomised controlled trial of aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 314, (7076): 1997; 253–257
10.1136/bmj.314.7076.253
PubMedWeb of Science®Google Scholar
[11]Weitz J.I.. Low molecular weight heparins. N Engl J Med. 337, (10): 1997; 688–698
10.1056/NEJM199709043371007
CASPubMedWeb of Science®Google Scholar
[12]Roman E.. Fetal loss rates and their relation to pregnancy order. J Epidemiol Community Health. 38, (1): 1984; 29–35
10.1136/jech.38.1.29
PubMedWeb of Science®Google Scholar
[13]Rote N.S.. Pregnancy-associated immunological disorders. Curr Opin Immunol. 1, (6): 1989; 1165–1172
10.1016/0952-7915(89)90010-1
PubMedWeb of Science®Google Scholar
[14]Harris E.N.. Annotation: antiphospholipid antibodies. Br J Haematol. 74: 1990; 1–9
10.1111/j.1365-2141.1988.00491.x-i1
CASPubMedWeb of Science®Google Scholar
[15]Branch D.W., Silver R.M., Blackwell J.L., Reading J.C., Scott J.R.. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 80, (4): 1992; 614–620
PubMedWeb of Science®Google Scholar
[16]Paceman A.M., Rehnberg K.A.. The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with lupus anticoagulant. Am J Obstet Gynecol. 173, (5): 1995; 1391–1396
10.1016/0002-9378(95)90622-3
PubMedWeb of Science®Google Scholar
[17]McIntyre J.A., Taylor C.G., Torry D.S., Wagenknecht D.R., Wilson J., Faulk W.P.. Heparin and pregnancy in women with a history of repeated miscarriages. Haemostasis. 23 Suppl 1: 1993; 202–211
PubMedWeb of Science®Google Scholar
[18]Fishman P., Falach-Vaknin E., Sredni B., Meroni P.L., Rudniki C., Shoenfeld Y.. Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid syndrome. J Rheumatol. 22, (6): 1995; 1086–1090
PubMedWeb of Science®Google Scholar
[19]Sherer Y., Levy Y., Shoenfeld Y.. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology. 39, (4): 2000; 421–426
10.1093/rheumatology/39.4.421
PubMedWeb of Science®Google Scholar
[20]Laskin C.A., Bombardier C., Hannah M.E., Mandel F.P., Ritchie J.W., Farewell V., et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 337, (3): 1997; 148–153
10.1056/NEJM199707173370302
PubMedWeb of Science®Google Scholar
[21]Clark A.L., Branch D.W., Silver R.M., Harris E.N., Pierangeli S., Spinnato J.A.. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet Gynecol. 93, (3): 1999; 437–441
PubMedWeb of Science®Google Scholar
[22]Empson M., Lassere M., Craig J.C., Scott J.R.. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev (2): 2005, [CD002859]
10.1002/14651858.CD002859.pub2
PubMedWeb of Science®Google Scholar
[23]Triolo G., Ferrante A., Ciccia F., Accardo-Palumbo A., Perino A., Castelli A.. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum. 48, (3): 2003; 728–731
10.1002/art.10957
CASPubMedWeb of Science®Google Scholar
[24]Kutteh W.H.. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 174, (5): 1996; 1584–1589
10.1016/S0002-9378(96)70610-5
PubMedWeb of Science®Google Scholar
[25]Kutteh W.H., Ermel L.D.. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol. 35, (4): 1996; 402–407
10.1111/j.1600-0897.1996.tb00501.x
PubMedWeb of Science®Google Scholar
[26]Shefras J., Farquharson R.. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol. 65, (2): 1996; 171–174
10.1016/0301-2115(95)02358-5
PubMedWeb of Science®Google Scholar
[27]Kajaa R., Julkunen H., Ammala P., Palosuo T., Kurki P.. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand. 72, (1): 1993; 63–66
10.3109/00016349309013355
PubMedWeb of Science®Google Scholar
[28]Spinnato J.A., Clark A.L., Pierangeli S.S., Harris E.N.. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol. 172, (2 pt 1): 1995; 690–694
10.1016/0002-9378(95)90595-2
PubMedWeb of Science®Google Scholar
[29]Marzusch K., Dietl J., Klein R., Hornung D., Neuer A., Berg P.A.. Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin. Acta Obstet Gynecol Scand. 75, (1): 1996; 922–926
10.3109/00016349609055029
PubMedWeb of Science®Google Scholar

Citing Literature

Volume104, Issue3

March 2009

Pages 223-225

Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome

Abstract

Objective

Method

Results

Conclusions

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome

Abstract

Objective

Method

Results

Conclusions

References

Citing Literature

References

Related

Information